EuroPharma Today

AZ’s Brillinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward

Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.

Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain

There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.

The End of The Euro: What Might It Mean For Pharma?

Companies struggle on how even to begin assessing impact of a possible Euro break-up.

The End of The Euro: What Might It Mean For Pharma?

Companies struggle on how even to begin assessing impact of a possible Euro break-up.